Antibodies News and Research

RSS

New diagnostic approach for Lyme disease

George Mason University researchers can find out if a tick bite means Lyme disease well before the bite victim begins to show symptoms.

25 May 2012

Astrocytes appear to retaliate against AD

When brain cells start oozing too much of the amyloid protein that is the hallmark of Alzheimer's disease, the astrocytes that normally nourish and protect them deliver a suicide package instead, researchers report.

23 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

Mimotopes can help develop new diagnostic tests for sleeping sickness

Each year many thousands of Africans contract sleeping sickness. The cause is a unicellular parasite, a trypanosome, which is transmitted by the bite of tsetse flies. First the parasite multiplies in blood and lymph, while evading the human immune system. It then lodges in organs like heart and kidneys and finally in the brain. Patients become disoriented, their sleeping pattern disintegrates and they get motor and mental problems.

23 May 2012

B cells in breast milk can produce HIV-neutralizing antibodies

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, and showed that the B cells in breast milk can generate neutralizing antibodies that may inhibit the virus that causes AIDS.

23 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Human cytomegalovirus associated with neovascular AMD

A team of researchers, including a scientist from the Viral Immunology Center at Georgia State University, have found that a type of herpesvirus infection of the eye is associated with neovascular age-related macular degeneration (AMD), a disease that causes blindness in the elderly.

22 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

ScreenCell, Affymetrix partner to distribute CTC platform

Affymetrix, Inc. and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

18 May 2012

Researchers identify novel base modification in RNA

Over the past decade, research in the field of epigenetics has revealed that chemically modified bases are abundant components of the human genome and has forced us to abandon the notion we've had since high school genetics that DNA consists of only four bases.

18 May 2012

Lenalidomide following stem cell transplant can halt progression of blood cancer

Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid-, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

17 May 2012

High-throughput sequencing can detect early signs of leukemia relapse

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

Dako, VARI partner to license, manufacture and distribute cancer diagnostics

Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody.

17 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

New mom receives surprise heart transplant

New mom Windy Hill, 38, of Kingsport, Tenn., was given the ultimate Mother's Day gift a little early after she was wheeled into the operating room at Vanderbilt University Hospital on April 20 to receive a mechanical pump to aid her failing heart and save her life.

14 May 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012